Who are CT-P55's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): MYL-1401H, CT-P43, CT-P41, PF-05280014.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ct-p55.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

CT-P55 — Competitive Intelligence Brief

CT-P55 (CT-P55) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: HER2-targeted monoclonal antibody (trastuzumab biosimilar). Area: Oncology.

phase 3 HER2-targeted monoclonal antibody (trastuzumab biosimilar) HER2 (human epidermal growth factor receptor 2) Oncology Biologic Live · refreshed every 30 min

Target snapshot

CT-P55 (CT-P55) — Celltrion. CT-P55 is a biosimilar of trastuzumab that targets HER2-positive cancer cells by binding to the HER2 receptor and blocking growth signaling.

Comparator set (4 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
CT-P55 TARGET	CT-P55	Celltrion	phase 3	HER2-targeted monoclonal antibody (trastuzumab biosimilar)	HER2 (human epidermal growth factor receptor 2)
MYL-1401H	MYL-1401H	Mylan Inc.	phase 3	HER2-targeted monoclonal antibody (trastuzumab biosimilar)	HER2 (human epidermal growth factor receptor 2)
CT-P43	CT-P43	Celltrion	phase 3	HER2-targeted monoclonal antibody (trastuzumab biosimilar)	HER2 (human epidermal growth factor receptor 2)
CT-P41	CT-P41	Celltrion	phase 3	HER2-targeted monoclonal antibody (trastuzumab biosimilar)	HER2 (human epidermal growth factor receptor 2)
PF-05280014	PF-05280014	Pfizer	phase 3	HER2-targeted monoclonal antibody (trastuzumab biosimilar)	HER2 (human epidermal growth factor receptor 2)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (HER2-targeted monoclonal antibody (trastuzumab biosimilar) class)

Celltrion · 3 drugs in this class
Mylan Inc. · 1 drug in this class
Pfizer · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). CT-P55 — Competitive Intelligence Brief. https://druglandscape.com/ci/ct-p55. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab